Table 1.

Responsiveness of GLOESS - analysed by standardised response mean and efficacy outcomes at week 24

Standardised response mean
(Initial secukinumab)
Efficacy of secukinumab
Week
0–12
(N = 83)
Week
0–24
(N = 83)
Responders
(%)
Secukinumab
week 0–24
(N = 83)
Placebo switchers
week 12–24
(N = 83)
GLOESS1.051.06ACR208774
Tender joint count1.031.35ACR506449
Swollen joint count0.911.18ACR703423
Patient global assessment of disease activity1.371.55HAQ-DI*8063
Physician global assessment of disease activity1.592.39PASI 757259
Pain1.321.53PASI 906245
HAQ-DI score1.321.32Resolution
of dactylitis (LDI=0)
6759
  • *HAQ-DI response is defined as an improvement of at least 0.35 score points compared to baseline (change ≤ −0.35)

  • N value for PASI response in secukinumab and placebo groups are 36 and 33; respectively. PASI response was calculated for patients with BSA ≥ 3 %.

  • BSA, Body Surface Area; LDI, Leeds Dactylitis Index